Spinal Muscular Atrophy Therapeutics: Where do we Stand? by unknown
REVIEW
Spinal Muscular Atrophy Therapeutics: Where do we Stand?
Constantin d’Ydewalle & Charlotte J. Sumner
Published online: 29 January 2015
# The Author(s) 2015. This article is published with open access at Springerlink.com
Abstract Spinal muscular atrophy (SMA) is an inherited neu-
romuscular disorder pathologically characterized by the de-
generation of motor neurons in the spinal cord and muscle
atrophy. Motor neuron loss often results in severe muscle
weakness causing affected infants to die before reaching 2
years of age. Patients with milder forms of SMA exhibit slow-
ly progressive muscle weakness over many years. SMA is
caused by the loss of SMN1 and the retention of at least 1
copy of a highly homologous SMN2. An alternative splicing
event in the pre-mRNA arising from SMN2 results in the pro-
duction of low levels of functional SMN protein. To date,
there are no effective treatments available to treat patients with
SMA. However, over the last 2 decades, the development of
SMA mouse models and the identification of therapeutic tar-
gets have resulted in a promising drug pipeline for SMA.
Here, we highlight some of the therapeutic strategies that have
been developed to activate SMN2 expression, modulate splic-
ing of the SMN2 pre-mRNA, or replace SMN1 by gene ther-
apy. After 2 decades of translational research, we now stand
within reach of a treatment for SMA.
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Introduction
Spinal muscular atrophy (SMA) is the most common autoso-
mal recessive cause of infant mortality, and was first described
by Werdnig and Hoffmann in the early 1890s [1, 2]. SMA
affects approximately 1 in 6000–1 in 10,000 live births, and
the carrier frequency is estimated to be 1 in 40–1 in 60 [3, 4].
The classical pathological hallmark of SMA is the loss of motor
neurons in the anterior horn of the spinal cord. Clinically, pa-
tients with SMA are classified into 1 of 5 types based on age of
onset and the inability to achieve motor milestones [5, 6]. Type
0 SMA is the most severe form, with onset at neonatal stages
and sometimes reduced movement in utero [6]. Patients with
SMA type 0 can never sit and, if untreated, they do not survive
beyond the first months after birth [6]. SMA type 1 is the most
common form of the disease, with a clinical onset usually be-
fore the age of 6 months. Affected infants never acquire the
ability to sit unsupported and often have no head control owing
to severe hypotonia and symmetrical paralysis [5, 6]. Patients
with SMA type 2 are characterized by an age of onset ranging
from 7 to 18 months. While these infants can sit unsupported,
they are unable to walk independently [5, 6]. In both types of
SMA, the diaphragm muscle is usually spared while intercostal
muscles are severely affected. This results in paradoxical
breathing; hence, the cause of death in patients with both type
1 and type 2 SMA is usually respiratory failure or complica-
tions of the respiratory tract [5, 6]. Prior to recent decades, most
patients with SMA type 1 did not survive beyond the first 2
years of life, while patients with type 2 SMA survived into
adulthood. [5, 6]. With increased use of respiratory and nutri-
tional support in recent decades, the average survival of patients
with SMA type 1 has increased [7, 8]. However, these inter-
ventions do not improve muscle strength. Patients with SMA
type 3 develop symptoms after the age of 2 years. They usually
achieve all major motor milestones, although many need
wheelchair assistance later in childhood or adulthood. Patients
with SMA type 4 usually have an onset in the second or third
decade of life. Muscle weakness is mild to moderate, and they
generally have no respiratory problems [5, 6].
A century after the first description of SMA, the underlying
genetic defect was identified [9]. Genetic linkage analyses and
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subsequent positional cloning in patients with SMA identified
a disease-associated 140-kb region that contained the dupli-
cated SMN on chromosome 5q13 [9]. In patients with SMA,
the telomeric copy of SMN (SMNT) on 5q13 is lacking usually
owing to large deletion mutations or, rarely, to point mutations
that disrupt survival motor neuron (SMN) function [9]. The
highly homologous centromeric copy SMN (SMNC), located
on the same chromosome, contains a critical translational si-
lent C > T substitution in an exonic enhancer at codon 280 in
exon 7 (6 base pairs downstream from the 5’ end of exon 7),
resulting in an alternatively spliced, truncated and nonfunc-
tional SMN protein (Fig. 1) [9, 10]. Currently, SMNT is re-
ferred to as SMN1, while SMNC is called SMN2. Humans
harbor at least 1 copy of SMN2. Soon after the discovery of
the disease-causing gene, it became clear that SMN2 copy
numbers inversely correlate with disease severity in most
cases [11].
Over the last 2 decades several repurposed drugs with neu-
roprotective effects have been tested in clinical trials in pa-
tients with SMA (reviewed in [12]). Unfortunately, their ef-
fectiveness in slowing disease progression was limited. In
2011, the US Food and DrugAdministration (FDA) approved,
for the first time, a phase I clinical trial of a drug developed
specifically for the treatment of SMA (‘RG3039’; Repligen/
Pfizer). Since then, other promising new therapeutic candi-
dates have been validated in preclinical models and are now
moving to clinical trials in human patients (Fig. 1). In this
review, we aim to highlight those promising SMA treatments
that are currently in advanced stages of development (summa-
rized in Fig. 2).
SMN
The SMN protein is a 294-amino acid polypeptide with a
predicted size of 38 kDa. It is highly conserved across species
and is expressed ubiquitously, raising the question of why
motor neurons are specifically vulnerable to SMN deficiency.
Both full-length and truncated SMNmRNA show similar half-
lives in primary fibroblasts, suggesting that mRNA stability
does not contribute to differences in SMN protein levels [13].
Levels of functional full-length SMN protein that self-
associate into the SMN complex inversely correlate with dis-
ease severity [9, 10, 14, 15]. In contrast, truncated SMN pro-
tein arising from SMN2 is unstable and is less efficient in self-
associating causing reduced levels of functional SMN com-
plex [15–17]. Thus, SMN2 fails to compensate for the loss of
SMN1, resulting in the development of SMA.
SMN localizes both to the cytoplasm and to very distinct
structures in the nucleus called Bgems^, the function(s) of
which are still under investigation [18]. SMN interacts with
a wide variety of known RNA binding proteins such as small
nuclear ribonucleic particles containing small nuclear RNAs
(snRNAs) and small nuclear ribonucleoproteins, as well as
other RNA binding proteins [18–20]. Several studies from
the Dreyfuss laboratory [21–24] have indicated that SMN
plays a crucial role in specific small nuclear ribonucleoprotein
biogenesis and spliceosome assembly, and hence in pre-
mRNA splicing (for a detailed review on the role of SMN in
spliceosome assembly, see [25]). In line with these findings,
SMN deficiency causes tissue-specific perturbations in
snRNA levels and widespread defects in splicing [24, 26,
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Fig. 1 Genetics of spinal muscular atrophy (SMA). SMA is caused by
mutation of SMN1 and reduced survival motor neuron (SMN) protein
levels. All patients retain at least 1 copy of the highly homologous
SMN2. SMN2 harbors a translational silent C > T substitution in a splice
enhancer sequence of exon 7, resulting in exon 7 skipping at the mRNA
level. The alternatively spliced SMN2mRNA encodes a truncated, highly
unstable, nonfunctional protein. A small fraction of SMN2 transcripts
contain exon 7 that encode a full-length, functional SMN protein
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27]. A search for specific genes showing perturbed splicing
and hence decreased expression in a Drosophila model for
SMN deficiency identified Stasimon, a protein required for
proper motor circuit function [28]. Deep RNA sequencing of
microdissected motor neurons and white matter from SMA
mice similarly identified mis-spliced genes that are critical
for synaptogenesis both in spinal cord and at neuromuscular
junctions [29]. The identification of specific genes whose pro-
cessing is perturbed by SMN deficiency might provide addi-
tional information about SMA pathology. Additionally, these
genes might represent disease modifiers and thus non-SMN
targets for potential new therapeutic strategies.
Some reports have demonstrated that SMN also local-
izes to cytoplasmic or neuritic granules in neurons suggest-
ing that SMN might also play a neuron-specific role in
mRNA transport or local mRNA processing [30–33]. A
recent report also indicated that reduced levels of SMN
are associated with an increase in microRNA-183 expres-
sion, causing downregulation of mammalian target of
rapamycin and, eventually, reduced global translation in
neurons [34]. These observations indicate that the mamma-
lian target of rapamycin pathway and specific microRNAs
might contribute to SMA pathology. Whether SMN has
other functions (in neurons and/or in other cell types) is
still under investigation.
SMA Mouse Models
Critical to understanding the pathogenic mechanism underly-
ing SMA, as well as to the development of (new) therapeutic
strategies, is the generation of animal models that recapitulate
human disease as closely as possible.
In contrast to humans, mice only harbor one Smn gene. In
1997, Schrank et al. [35] reported that homozygous deletion
of Smn causes massive cell death during early embryonic de-
velopment. This observation emphasizes that some SMN is
required for survival of all cells. Embryonic lethality of Smn–/–
mice was rescued by inserting 1 (founder line 89) or 8 (foun-
der line 566) copies of the human SMN2 [36]. At birth, Smn–/–/
SMN2+/+ mice appear normal, irrespective of the number of
SMN2 copies [36]. However, low-copy animals quickly dete-
riorate with tremor in the hind limbs, reduced righting reflex,
severe muscle weakness, and loss of body weight followed by
death at the age of 6 days [36]. Interestingly, high-copy Smn–/
–/SMN2+/+ mice do not show any obvious phenotype and live
a normal life, consistent with the inverse correlation of disease
severity and SMN2 copy numbers in patients with SMA [36].
Like in humans, most transcripts arising from SMN2
lack exon 7, and Smn–/–/SMN2+/+ mice have 10- to


























Fig. 2 Pipeline of spinal muscular atrophy drugs. The status of 1) SMN2 promoter activating drugs, 2) SMN2 splicing modulating drugs, and 3) SMN1-
replacing strategies that are in advanced stages of development and described in this review. FDA = US Food and Drug Administration
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Subsequently, a transgene harboring a 3.4-kb portion of the
human SMN promoter followed by a truncated SMN2 cDNA
(SMNΔ7) clone was introduced into the severe SMA mouse
model [37]. The resulting Smn–/–/SMN2+/+/SMNΔ7+/+
(BDelta7^) mice show a prolonged survival (with a mean sur-
vival of 13 days) compared with the severe Smn–/–/SMN2+/+
mice [37].
In parallel work, another mouse model with a SMA-like
phenotype was generated [38]. This other widely used model
is referred to as the BTaiwanese^ SMAmouse model. Homozy-
gous deletion of mouse Smn also caused embryonic lethality in
this study, confirming that SMN is required in early embryonic
stages [38]. Transgene insertion of a 115-kb human genomic
region containing SMN2 and (parts of) neighboring genes res-
cued embryonic lethality [38]. The resulting SMA-like mice
were categorized into 3 groups based on the severity of the
phenotype. Type 1 SMA mice displayed body weight loss, did
not develop furry hair, and died by the age of 10 days [38]. Mice
with intermediate severity (type 2) showed bodyweight loss and
poor activity, and died between 2 weeks and 4 weeks of age
[38]. Mice that survived and bred normally but had shorter tails
were classified as type 3 [38]. This mouse line has subsequently
been bred at The Jackson Laboratory, resulting in a more ho-
mogenous phenotype. Other mouse models with modifications
of the aforementioned SMAbackgrounds, as well as conditional
mouse models of SMA, have been reported. Development of
mouse models of mild SMA have been challenging (for a re-
view of SMA mouse models, see [39]).
Severe SMA mouse models have been studied extensively
to determine the pathological basis of weakness and reduced
survival. Interestingly, although SMA mice do exhibit some
motor neuron loss at end-stages of the disease, it varies de-
pending on spinal cord region and, overall, may not be suffi-
cient to account for the magnitude of weakness [40, 41]. Sim-
ilarly, denervation ofmuscle is restricted to fewmuscle groups
[42]. This has indicated that motor neuron dysfunction rather
than death drives clinical manifestations in early stages of
disease. Indeed, it has been demonstrated that neuromuscular
junctions [41, 43–47], as well as synaptic inputs onto motor
neurons in the spinal cord [40, 45], are structurally and func-
tionally abnormal. These functional changes are associated
with the presence of widespread hypotrophic muscle fibers
consistent with a lack of myofiber maturation [44, 47].
Is SMA a Neurodevelopmental or a Neurodegenerative
Disorder, or Both?
Unlike the inexorable progressive disease course of the motor
neuron disease ALS, loss of muscle power (or simply failure
to gain muscle strength) in SMA may be most evident at
disease onset with subsequent stabilization for many years.
This has led to the hypothesis that some aspects of SMA are
due to impaired development of the motor unit. Histopatho-
logical analyses of spinal cords from patients with severe
forms of SMA have shown both loss of anterior horn cells
and signs of immature and mismigrated motor neurons. The
number of largemyelinated axons in ventral roots are reduced,
but remaining axons show reduced diameters [48–51]. Neu-
romuscular junctions in SMA type 1 muscle show persistent
expression of the fetal subunit of the acetylcholine receptor
[52], and myofibers in patients with SMA type 0 and type 1
show ongoing apoptosis, as well as immature morphology
[48, 51]. Together, these data suggest that while neuronal de-
generation plays an important role, at least in patients with
severe SMA, poor development of the motor unit may also
occur (schematically shown in Fig. 3). Severe SMA mice
appear to show a similar combination of both degenerative
and developmental pathology. While there is motor neuron
loss and denervation of a limited number of muscles, there is
also impaired formation of mature, complex neuromuscular
junctions, and retarded myofiber growth [40, 44, 47].
Delayed maturation of the motor unit suggests that there is
a temporal requirement for SMN protein to develop a fully
functional motor circuit. SMN expression is developmentally
regulated in rodents and in humans. High expression is ob-
served in gestational and early neonatal stages, followed by a
sharp decrease to basal levels, which are maintained [52–55].
At the cellular level, SMN appears to be expressed at high
levels in motor neurons at neonatal stages in rodents, nonhu-
man primates, and humans [52–55]. Transgenic mice that ex-
press SMN in an inducible, constitutive manner have indicat-
ed that restoration of SMN levels by early postnatal
postsymptomatic stages is capable of substantially increasing
survival [56, 57]. A recent study used a transgenic approach to
ablate SMN expression in an inducible manner in mice, and
confirmed that early SMN expression is required for proper
development of the motor unit [58]. Interestingly, reducing
SMN levels in adult mice had relatively little effect, further
suggesting a temporal requirement for SMN [58]. Insensitivity
to SMN deficiency emerged abruptly at postnatal day 17,
which coincides with the time in development when mature
neuromuscular junctions are established in mice [58]. The
ability to regenerate mature neuromuscular junctions after in-
jury in adult mice was impaired in the absence of SMN, sug-
gesting that SMN might play a role in the maintenance of
structural and functional integrity of the motor unit [58].
Together, these data provide evidence that SMN deficiency
i n e a r l y s t a g e s o f d e v e l o pm e n t m a y c a u s e
neurodevelopmental abnormalities that may be relevant to pa-
tients with type 1 SMA (Fig. 3), while milder forms of SMA
might be predominantly characterized by the inability tomain-
tain integrity of motor units after their establishment. This
could, in part, account for the differences in age of disease
onset, disease severity, and survival between the types of
SMA (Fig. 3).
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Therapeutic Strategies
Several neuroprotective drugs have been tested in SMA clin-
ical trials. Riluzole is the only FDA-approved drug for the
treatment of amyotrophic lateral sclerosis (ALS). Phase I clin-
ical trials in patient with type I SMA showed that it was tol-
erated and that it showed similar pharmacokinetics in patients
with SMA to those seen in patients with ALS [59, 60]. How-
ever, there was no evidence of efficacy, and these trials were
complicated by patient drop out due to death, highlighting the
challenges of clinical trials in this very fragile patient
population.
Trophos developed a cholesterol-like compound
(TRO19622, olexosime), which shows remarkable neuropro-
tective properties [61, 62]. Like riluzole, it was originally de-
veloped as a potential treatment for ALS [61, 62]. While its
exact mode of action is not completely understood, it has been
granted an orphan drug status for the treatment of ALS in the
USA and for spinal muscular atrophy in Europe [62]. Recent-
ly, Trophos reported preliminary results at the 2014 Families
of SMA meeting, indicating that olesoxime may prevent mo-
tor function loss in patients with type 2 and type 3 SMA, and
other disease-related outcomes compared with the placebo-
treated group over a period of 2 years in a phase II clinical
trial (Fig. 2) [63]. Follow-up trials will indicate whether these
preliminary results are clinically relevant.
Ever since the discovery of the unique genetics of SMA,
SMN induction has been considered one of the most promis-
ing treatment strategies for the disease. Several approaches
that indirectly induce SMN expression (e.g., the FDA-
approved cyclo-oxygenase inhibitor celecoxib) [64] or that
improve the SMA phenotype in an SMN-independent manner
(e.g., the muscle growth pathway involving follistatin/
myostatin) [65, 66, 67] have been tested in preclinical settings.
However, most of them have been shown to have only limited
effect in mouse models of SMA, might have side effects, or
have low central nervous system (CNS) penetrance. However,
several new drugs/biologics are entering clinical trials in pa-
tients, including those that aim to 1) increase SMN2 expres-
sion; 2) modulate SMN2 splicing; and 3) replace SMN1 by
gene therapy (Fig. 2). Some of these new therapeutic strate-
gies are discussed below.
SMN2 Promoter Activation
Reduced SMN levels characterize SMA, and all patients with
SMA retain at least 1 SMN2 copy. An attractive potential
therapeutic approach would be to increase the SMN2 promoter
Prenatal to neonatal Neonatal to adult Neonatal Adult
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Fig. 3 Survival motor neuron (SMN) may be crucial for normal
development and postnatal maintenance of the motor unit. In prenatal
and perinatal stages, terminally differentiated motor neurons (MN) in
the spinal cord express high levels of SMN. At these stages, developing
motor axons are still small in diameter, but reach their target muscle
correctly. The immature synaptic inputs in the spinal cord, as well as
immature neuromuscular junctions (NMJs), are developing in neonatal
stages. Once the motor unit is fully developed, SMN levels drop to
normal levels. These levels are sufficient to maintain motor unit
function and respond to nerve injury. In severe forms of spinal
muscular atrophy (SMA; type 0 and 1), very low levels of SMN cause
incomplete maturation of the motor unit. Classical features include
incomplete development of synaptic inputs of motor neurons in the
spinal cord and partial development of NMJs, eventually causing severe
muscle weakness and premature death. In milder forms of SMA (types 2–
4), the motor unit has completely developed, but SMN levels are too low
to maintain structural and functional integrity of the motor unit. SMN
levels are also too low to respond to nerve injury. Motor neuron loss
and axonal degeneration eventually causes muscle weakness and atrophy
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activity (Fig. 4). Initial attempts to ameliorate the SMA phe-
notype were focused on increasing SMN2 expression using
histone deacetylase (HDAC) inhibitors. HDACs deacetylate
histones thereby suppressing transcriptionally active genes. In
2001, Chang et al. [68] reported, for the first time, that the
HDAC inhibitor sodium butyrate increased SMN levels in
patient-derived cells and in mouse models of mild SMA.
Since then, other reports have indicated that several HDAC
inhibitors are able to increase SMN levels in patient-derived
cells and in various mouse models of SMA. These HDAC
inhibitors include valproic acid (VPA) [69, 70], the benzamide
M344 [71], and the hydroxamic acid class of HDAC inhibi-
tors, including suberoylnanilide hydroxamic acid [72–74],
LBH589 [75], and trichostatin A [76, 77]. All HDAC inhibi-
tors increased SMN2 transcriptional activity, probably by their
inhibitory effect on HDAC1 and/or HDAC2 [78]. However,
these HDAC inhibitors had variable effects on SMN levels
and variably improved the SMA phenotype in mice [73, 76,
77] perhaps owing, in part, to their low potency. Some of the
HDAC inhibitors also exhibit low penetrance in the CNS. In
addition, these compounds are pan-HDAC inhibitors, sug-
gesting that they may have negative side effects. Despite their
modest efficacy in preclinical models, HDAC inhibitors were
evaluated in clinical trials in patients with SMA because 2 of
them were already used in clinical practice for other indica-
tions. Clinical trials of VPA and phenylbutyrate indicated that
HDAC inhibitors had little or no effect in patients with SMA
type II and type III [79–81]. Patients treated for 1 year with
VPA and L-carnitine showed excessive weight gain, affecting
motor function in some cases [80].Motor function appeared to
be slightly improved when corrected for body weight in
treated cases aged 2–3 years, but not in older cases [80].
These observations suggest that HDAC inhibitors might be
beneficial when administered early [80]. In adult patients
with type 3 SMA treated with VPA, only compound mus-
cle action potentials modestly improved over the 1-year
treatment period [81].
Besides acetylation/deacetylation, histones can also be
me thy l a t ed /deme thy l a t ed , (de )phospho ry l a t ed ,
(de)ubiquinated and/or (de)sumoylated. In addition, DNA
can be methylated at CpG islands, which also represses gene
expression. All of those modifications have an impact on the
chromatin structure, and hence on transcriptional activity
[82–84]. For example, Hauke et al. [85] reported that
SMN2 is silenced by DNA methylation specifically at
CpG islands within or in close proximity of the SMN2
promoter. This observation suggests that targeting only 1
epigenetic marker of transcriptional activity might not be
sufficient to increase expression levels of a given gene,
or SMN2 specifically. A systematic analysis of all these
modifications might identify new promising therapeutic
targets to increase SMN2 promoter activity and conse-
quently increase SMN2 expression.
An alternative strategy to increase SMN2 promoter activity
was used by Jarecki et al. [86] in 2005 with support from
BFamilies of SMA^ [86]. In this study, an unbiased screen of
550,000 compounds was performed using a genetically
engineered SMN2 promoter assay in NSC34 cells, a motor
neuron-like cell line. The most potent compounds that in-
















Fig. 4 Mechanism of SMN2 promoter activation drugs. SMN2 promoter activating strategies aim to induce SMN2 expression, resulting in increased full-
length and truncated SMN mRNA and protein levels
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level) in this assay, as well as in patient-derived fibroblasts,
were of the class of quinazolines [86]. In a follow-up study,
the authors identified the scavenger mRNA decapping en-
zyme DcpS as the target of these compounds [87]. DcpS
removes the residual 5’ cap after 3’–5’ degradation of mRNA.
Now referred to as Repligen/Pfizer compound RG3039, this
SMN2 promoter activator only modestly increases SMN
mRNA and SMN protein levels in various mouse models of
severe and mild SMA [88–90]. Despite this modest increase,
the DcpS inhibitor effectively extends the lifespan of SMA
mice after oral administration [88–90]. Although the exact
mechanism through which DcpS inhibition partially rescues
the SMA phenotype is still under investigation, RG3039 is
close to entering phase I clinical trials (Fig. 2).
Modulation of Splicing
As SMN2 gene expression results in an alternative spliced,
truncated, and nonfunctional product, an alternative approach
for therapy development has focused on changing the splicing
of SMN2 pre-mRNAs (Fig. 5). Antisense oligonucleotide
(ASO) technology was initially developed to downregulate
gene expression by targeting mRNAs to induce their degrada-
tion or block their translation [91]. Advances in antisense
chemistry now allow application of this technology to manip-
ulate pre-mRNA splicing [91].
One approach to modulate splicing of exon 7 in SMN2was
focused on shifting the competition between the 3’ splice site
of exon 7 and exon 8 in favor of exon 7 inclusion by using
antisense technology. Favoring exon 7 inclusion increased
SMN protein levels dose-dependently in HeLa cells
transfected with genetically engineered U7 snRNAs targeting
a sequence partially overlapping the intron 7/exon 8 boundary
(anti-SMN U7 snRNAs) [92].
Another approach to modulate exon 7 splicing aimed to
block the intronic splice repressor Element1 (ISS-E1) se-
quence upstream of exon 7, as deletion of ISS-E1 increased
exon 7 inclusion in HeLa cells [93, 94]. So-called bifunctional
RNAs inhibit ISS-E1 and recruit SR proteins (conserved
serine- and arginine-rich proteins involved in pre-mRNA
splicing) to the SR recruitment sequence in the bifunctional
antisense RNA to promote exon 7 inclusion [93]. These bi-
functional RNAs increased exon 7 inclusion and SMN protein
levels in transfected in HeLa cells and in patient-derived cells
[93]. In addition, intracerebroventricular (ICV) delivery of
bifunctional antisense RNAs in SMA mice variably increased
SMN protein levels in the CNS system [93]. However, the
phenotypic benefit of delivering bifunctional antisense RNAs
in the CNS in SMAmice was limited [93]. Morpholino-based
antisense treatment targeting Element1 by single ICV delivery
elicited robust SMN protein induction in the CNS and muscle
[95]. In addition, this treatment strategy improved survival,
weight, motor function, and neuromuscular pathology in both
severe and intermediate mouse models of SMA [95].
The identification of the intronic splicing silencer N1 (ISS-
N1) element downstream of the 5’ splice site in intron 7 pro-
vided a third target for antisense technology to modulate
SMN2 splicing [96]. Deletion of ISS-N1 promoted exon 7
inclusion, indicating that ISS-N1 was another promising














Fig. 5 Mechanism of SMN2 splicing modulation drugs. Antisense oligonucleotides (ASOs) or chemical compounds promote exon 7 retention in the
SMN2 pre-mRNA, resulting in increased full-length SMN mRNA and protein levels
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laboratories has indicated that ASOs targeting ISS-N1 dramat-
ically promoted exon 7 inclusion to near 100% of the primary
transcripts, and increased SMN protein levels in transfected
cell lines, in patient-derived cells, and in mouse models of
SMA [96–100].
Treatment of adult heterozygous or wild-type transgenic
SMN2 mice twice a week (by tail vein injections) with this
ASO resulted in a dose- and time-dependent increase in exon
7 inclusion in liver and kidney [98]. However, exon 7 inclu-
sion rate was not affected in spinal cord of these animals as the
ASO did not penetrate the blood–brain barrier (BBB) when
injected systemically at this age [98]. An independent study
using a different ASO targeting ISS-N1 (nucleotide range 13–
33 downstream of exon 7) with a different backbone chemis-
try and delivered ICV to SMA mice increased SMN protein
levels throughout the spinal cord and increased body weight
and righting reflex [101]. In this study, the effect of the ASO
on lifespan was not reported [101].
To investigate the effect of ASO in the spinal cord, Hua
et al. [102] infused ASO 10–27 continuously for 7 days in the
right lateral ventricle at various doses in adult mild SMAmice
(type 3 SMA, Smn+/-/SMN2+/+ with 4 copies of SMN2). ASO
treatment resulted in an almost complete rescue of exon 7
exclusion and increased SMN protein levels throughout all
levels of the mouse spinal cord [102]. In addition, in vivo
half-life of the ASO appeared to be very long, as the effect
of the ASO was still observable 6 months after completing the
7-day treatment [102].
Alternatively, a single ICV administration of morpholino-
based oligomers targeting ISS-N1 in neonatal Delta7 mice
extended the lifespan to > 100 days [99, 100]. Delayed deliv-
ery of the morpholino to the CNS only had moderate efficacy
with mild changes in lifespan, indicating that increasing SMN
levels in early stages are critical to improve the SMA pheno-
type [99, 100].
Finally, the Krainer laboratory investigated the effective-
ness of central versus systemic administration of ASO in the
severe BTaiwanese^ SMA mouse model [103]. In this study,
ASO was administered intracerebroventricularly on day 2, or
subcutaneously on day 1 or day 3 [103]. Delivery of the ASO
in the CNS efficiently corrected SMN2 splicing in brain and
spinal cord, leading to increased SMN protein levels but only
modestly extended survival (10 vs 16 days) [103]. In marked
contrast, systemic delivery of the ASO resulted in a median
survival of > 100 days [103]. Combining ICVand subcutane-
ous (SC) injections or 2 additional SC injections resulted in
increased survival (173 and 137 days, respectively) [103].
Most rescued mice had nearly normal motor function, but ears
and tails developed necrosis and were eventually lost [103].
ICV injection of the ASO resulted in a marked increase in
exon 7 inclusion in brain and spinal cord, but had very limited
effects in peripheral organs [103]. SC injections also increased
exon 7 inclusion, including in brain and spinal cord, owing to
the incomplete closure of the BBB in neonates and/or retro-
grade transport of the ASO [103]. The marked difference be-
tween ICV and SC injections on the rescue of the phenotype
suggests that peripheral restoration of SMN expression is cru-
cial for survival in this mouse model [103]. On a histological
level, motor neuron counts, muscle fiber size, and neuromus-
cular junction integrity were similar between treated mice and
their heterozygous controls [103]. Finally, the authors attrib-
uted the restoration of circulating insulin-like growth factor-1
secreted from the liver in treated SMA mice as a factor con-
tributing to the rescue of the SMA phenotype [103]. These
findings suggest that organs other than the CNS might con-
tribute to SMA pathogenesis in mice. It is unclear if these
findings are relevant to human disease, as the majority of
patients with SMA do not have peripheral defects.
Based on the extraordinary effects of ASO 10-27 (now
referred to as ISIS-SMNRx), ISIS Pharmaceuticals partnered
with Biogen Idec and completed phase I (in 2013) and phase II
(in 2014) clinical trials (Fig. 2). ISIS Pharmaceuticals/Biogen
Idec reported that ISIS-SMNRx was well tolerated when ad-
ministered intrathecally as a single dose. ISIS-SMNRx was
also observed in the cerebral spinal fluid, indicating that the
drug half-life in the human CNS is very long. In addition,
single or multiple doses of ISIS-SMNRx also increased
SMN protein levels and moderately increased the
Hammersmith Functional Motor Scale-Expanded score, a
functional read-out for motor function.
Given the complementary sequence of ASOs, ISIS-
SMNRx very specifically modulates exon 7 splicing. Work
in the mouse model has indicated that systemic delivery of
the ASO has a superior effect on the SMA phenotype. Wheth-
er this would be the case in humans affected with SMA is thus
far an unanswered question. While repeated intrathecal ad-
ministration is an invasive route of delivery, the frequency of
delivery is once every 3 months because of the long drug half-
life.
In order to identify small molecules that might have similar
effects on exon 7 splicing, there have been extensive screening
efforts for chemical compounds that induce exon 7 inclusion.
In 2001, aclarubicin was identified as a compound that in-
creased exon 7 inclusion and SMN protein levels in in
patient-derived fibroblasts [104]. Anthracycline antibiotics
such as aclarubicin are widely used as part of conventional
chemotherapy. However, their long-term use is prohibited ow-
ing to toxicity issues.
Based on the structural similarity to aclarubicin, Paratek
Pharmaceuticals screened their tetracyclines derivatives li-
brary [105]. One derivative, PTK-SMA1, promoted exon 7
inclusion but did not change the splicing pattern of other
genes, suggesting a specific effect on SMN2 exon 7 splicing
[105]. PTK-SMA1 also increased exon 7 inclusion and SMN
protein levels in a mouse model of mild SMA [105]. Paratek
Pharmaceuticals is now in the final stages of optimizing PTK-
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SMA1 as an investigational new drug (Fig. 2). One challenge
to this drug has been limited BBB penetration.
More recently, orally available compounds that modify
SMN2 splicing in a quite specific manner have been identified
by PTC Therapeutics and Roche in partnership with the SMA
Foundation [106]. This study marks a major breakthrough in
the search of compounds that specifically modulate a single
splicing event. The compounds dose-dependently increased
full-length SMN mRNA levels and SMN protein levels in
patient-derived fibroblasts [106]. RNA sequencing indicated
that these modifiers did not affect widespread gene expression
changes as only 6 genes were up- or downregulated by a factor
of 2 or more [106]. In addition, analysis of annotated splice
junctions indicated that these compounds were highly specific
in promoting SMN2 exon 7 inclusion [106]. These modifiers
also increased motor function and dramatically extended sur-
vival of 2 different SMA mouse models when administered
systemically by oral gavage and/or by intraperitoneal admin-
istration [106]. Independently, Novartis identified another
orally available small molecule that is able to modulate splic-
ing of SMN2 and increase SMN protein levels in cell lines
derived from SMA mouse models and patients with SMA
[107]. Although the exact mechanism of action of these com-
pounds is still not understood, clinical trials are being planned
in Europe and the USA to evaluate the effectiveness of these
orally available SMN2 splice modifiers (Fig. 2) [106].
Gene Therapy
Rather than increasing the expression of endogenous full-
length SMN2 by activating its promoter or by modulating
splicing of exon 7, some groups have focused on replacing
SMN1 by gene therapy (Fig. 6). Ground-breaking work from
the Kaspar laboratory [108] in 2010 showed that gene therapy
had marked efficacy SMA mice. In this report, SMN cDNA
under the control of a strong promoter was encapsulated by
the self-complementary adeno-associated virus serotype-9
(scAAV9) [108]. The scAAV9 gene therapy delivered intra-
venously resulted in a marked increase in SMN protein levels
in brain and in motor neurons of spinal cord, indicating that
scAAV9 is able to traverse the BBB and has neurotropism.
scAAV9 treatment also showed a striking increase in SMN
protein levels in skeletal muscle [108]. One- or 2-day-old
injected Delta-7 mice lived profoundly longer than the control
mice (mean lifespan 250 vs 15.5 days, respectively) [108]. In
addition, locomotor function, weight, and neuromuscular
transmission were partially rescued [108]. Interestingly, when
mice were injected at later time points, transduction with
scAAV9 distributed more towards glial cells than motor
neurons. Strikingly, lifespan of these treated animals dra-
matically decreased, suggesting that there is a very narrow
therapeutic window in SMA mice [108]. The scAAV9 also
proved to have clinical potential, as it traversed the BBB
and efficiently infects cells in dorsal root ganglia and mo-
tor neurons within the whole spinal cord in a (1-day-old,
injected) nonhuman primate [108]. Other work has demon-
strated that transgene expression persists in the CNS (both
motor neurons and glial cells in spinal cord), as well as
skeletal muscles when nonhuman primates were systemi-
cally treated at various ages [109]. In addition, local
scAAV9 injection into the cerebral spinal fluid of piglets
efficiently transduced motor neurons throughout the spinal
cord and resulted in robust transgene expression [109].
In other studies, AAV8–SMN1 has been studied in SMA
mice. Injection of AAV8–SMN1 cDNA controlled by a pro-
moter specific for the CNS resulted in increased weight gain,
motor function, and a median survival benefit of 50 days
[110]. However, the survival curve demonstrated a bimodal
distribution, with a first group dying between 17 and 27 days,
and the second group between 58 and 66 days [110]. One
possibility is that the first group had a more severe SMA
phenotype at the time of intervention. Alternatively, the first
group might have had a more profound immune response
against the AAV8 capsid compared with the second group
[110]. The self-complementary version of this virus
(scAAV8) showed more efficient targeting of choline
acetyltransferase (ChAT) -positive cells in the spinal cord
compared with the AAV8 version [110]. Treatment with
scAAV8-SMN1 resulted in a striking improvement of median
survival of 157 days [110]. Additionally, scAAV8-treated an-
imals showed body weight gain, improved motor function,
and remained ambulatory throughout their life. In both treat-
ment strategies, animals developed hind limb necrosis albeit
milder in the scAAV8-treated animals compared to the AAV8-
treated mice [110]. AAV8-treated animals also displayed an
increased number of choline acetyltransferase (ChAT)-
positive cells compared with untreated animals, indicating that
increasing SMN levels prevents motor neuron loss in the spi-
nal cord. This results in the preservation of myofiber and neu-
romuscular junction architecture [110].
To determine if the route of injection significantly affects
the degree to which the SMA phenotype is corrected, intrave-
nous (IV) and ICV treatment was performed in 3-day-old
SMAmice (with the same dose of scAAV9) [111]. Consistent
with the original report, IV injection increased SMN protein
levels in brain and spinal cord [111]. Brain SMN levels were
increased dramatically in ICV-injected mice [111]. Both treat-
ment strategies improved motor function of SMA mice [111].
Similar to the report of Passini et al. [110], a bimodal survival
curve was observed in the IV-treated cohort, with some mice
surviving only 25–35 days, while the remainingmice survived
>200 days [111].
ICVor IV delivery of scAAV9 SMN in the severe SMN2
mouse model (with an average lifespan of 8 days) at day 1
(when the mice are already symptomatic) also results in
weight gain (ICV better than IV) with robust SMN expression
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in brain and spinal cord [112]. IV-injected animals showed
minimal improvement of the skeletal muscle architecture,
while ICV displayed a slight improvement in muscle fiber
area [112]. Nevertheless, motor function was not dramatically
improved [112]. The extraordinary results with viral-mediated
gene transfer in SMA mice and in nonhuman primates recent-
ly led AveXis to start a phase I clinical trial at Ohio State
University (OSU) to assess safety and tolerability of intrave-
nously injected scAAV9-SMN (referred to as BchariSMA^) in
patients with SMA type 1 (Fig. 2). Patients who receive cha-
riSMA must carry biallelic SMN1 mutations and, at best, 2
copies of SMN2, and should have disease onset at birth or
before the age of 6 months. These stringent inclusion criteria
are, in part, to target patients as early in the disease course as
possible. In addition, there are manufacturing limitations of
the scAAV9 virus at this time that limit the size of an infant
who can be treated systemically. Independently, Genzyme is
also developing a viral-mediated gene therapeutic strategy to
treat SMA (Fig. 2).
Conclusions and Future Perspectives
As evident from this review (summarized in Fig. 2), there has
been enormous progress in SMA therapeutics development in
recent years. Several drug candidates have shown remarkable
efficacy in mouse models of SMA, and we now stand on the
verge of determining whether they will have efficacy in
patients with SMA. Despite this optimism, there are still a
number of questions that remain unanswered.
First, we need to address in what ways the SMA mouse
models do or not recapitulate disease features of human
SMA. The impairments of motor behavior and survival in
SMA mice are likely relevant to human patients, but SMA
mice at end-stage show significantly less motor neuron
loss, as well as myofiber atrophy, compared with human
patients. Whether patients with SMA have an early phase
of disease characterized by functional abnormalities of mo-
tor neurons prior to degeneration similar to what is ob-
served in mice and when this phase occurs is critical to
address as this will be the optimum time for therapeutic
intervention. Another issue is that many SMA mouse
models develop ear, tail, and/or toe necrosis, and cardiac,
gut, and urinary pathology that likely contribute to reduced
survival in SMA mice, but may or may not be relevant in
the human disease. These observations raise questions
about whether cell types other than motor neurons show
vulnerability to SMN deficiency in humans, and whether
these contribute significantly to human SMA pathology.
Increasingly, it is recognized that preclinical testing of nov-
el therapeutics in SMAmouse models needs to include assess-
ments most relevant to patients, including motor neuron num-
ber, neuromuscular junction innervation, and muscle patholo-
gy, rather than simply survival. In addition, to overcome a bias
based on mouse model-dependent outcomes, it is ideal to
evaluate at least 2 SMA mouse models when investigating










Exon 1-5 6 7 8












Fig. 6 Mechanism of SMN1 replacement by gene therapy. Using adenovirus-associated viruses, SMN1 cDNA is incorporated in the human genome,
resulting in increased full-length SMN mRNA and protein levels
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Second, it is clear from work done in SMA mice that re-
storing SMN levels genetically or pharmacologically early
during development appears to be beneficial to extend surviv-
al, body weight, and motor function. Whether we can extrap-
olate this to patients with SMA is a matter of debate. An
accurate profile of SMN protein expression both in controls
and in affected individuals might shed light on amore accurate
Bwindow of opportunity^ to induce SMN expression in
humans. Information on how SMN expression in humans is
regulated both at the transcriptional and post-transcriptional
level is lacking. The fact that HDAC inhibitors only have a
limited effect on SMN induction suggests that mechanisms
other than repressive deacetylated histones might contribute
to SMN silencing. A detailed investigation of these regulatory
mechanisms might contribute to our insights on how SMN
expression is temporally regulated in specific human cell
types. Similarly, little is known about the splicing pattern
of SMN2 over time and/or in different human cell types.
Mapping the frequency profile of exon 7 inclusion in
SMN2 might be useful when developing drugs that modu-
late SMN2 splicing.
Given the extraordinary rescue of the SMA phenotype in
mouse models by some of the drugs, combining different
strategies might have additive effects on SMN expression,
and hence be more beneficial in treating SMA. For example,
increasing SMN transcript levels using an SMN2 promoter-
activating drug in addition to a splicing modulator might in-
crease SMN to levels higher than by treatment with only one
of those drugs.
Finally, the genetics of SMA have led to the development
of strategies to manipulate SMN expression directly. Howev-
er, less extensive efforts have been devoted to identifying
mechanisms that contribute to SMA pathogenesis either inde-
pendently of SMN insufficiency or indirectly as a result of
SMN insufficiency. An in-depth analysis of disease pathogen-
esis might identify novel disease modifiers (others than
SMN2) as therapeutic targets
As the SMA drug pipeline has been growing and evolving
rapidly over the last decade, and with dedicated researchers in
the SMA field collaborating worldwide, we are hopeful that
we stand, for the first time, within reach of a treatment for
SMA.
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